AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18319306 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 38
Study 15944074 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella typhi vaccine
Number of subjects: 30
Study 15944074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12886210 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocycling for 500 cycles between 5 degrees and 55 degrees C with a dwell time of 30 seconds
Number of subjects: 120
Study 12886210 — intervention group
Group type: COMPARATOR
Intervention: No thermocycling treatment
Number of subjects: 120
Study 10073863 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL) raising treatment with nicotinic acid
Number of subjects: 468
Study 10073863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL) lowering therapy with hydroxymethylglutaryl-coenzyme A reductase inhibitor
Number of subjects: 468
Study 10073863 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (beta-carotene and vitamins E and C)
Number of subjects: 468
Study 10073863 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (warfarin)
Number of subjects: 468
Study 10073863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interventions
Number of subjects: 468
Study 10073863 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 468
Study 8898629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 2213
Study 8898629 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 2213
Study 1798006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 2 mg
Number of subjects: 0
Study 1798006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg
Number of subjects: 0
Study 1798006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6336634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation
Number of subjects: 21
Study 6336634 — intervention group
Group type: COMPARATOR
Intervention: No cranial irradiation
Number of subjects: 21
Study 6336634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation (non-randomized group)
Number of subjects: 21
Study 31746224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with chemotherapy
Number of subjects: 0
Study 31746224 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 0
Study 30827869 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected walking group (SSWG; n = 25)
Number of subjects: 48
Study 30827869 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n = 23)
Number of subjects: 48
Study 29599033 — intervention group
Group type: COMPARATOR
Intervention: Liposomal bupivacaine (EXP)
Number of subjects: 32
Study 29599033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine cocktail (ROP)
Number of subjects: 32
Study 29599033 — intervention group
Group type: COMPARATOR
Intervention: Both EXP and ROP
Number of subjects: 32
Study 27351443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic program
Number of subjects: 69
Study 27351443 — intervention group
Group type: COMPARATOR
Intervention: Vacation group
Number of subjects: 69
Study 24939380 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrothermal arthroscopic capsulorrhaphy (ETAC)
Number of subjects: 54
Study 24939380 — intervention group
Group type: COMPARATOR
Intervention: Open inferior capsular shift (ICS)
Number of subjects: 54
Study 22078631 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological modulators (PMs) with antioxidant action (MF Templar®)
Number of subjects: 64
Study 22078631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22078631 — intervention group
Group type: EXPERIMENTAL
Intervention: MF Templar®
Number of subjects: 64
Study 22078631 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (same amount of catechins as MF Templar®)
Number of subjects: 64
Study 22078631 — intervention group
Group type: EXPERIMENTAL
Intervention: MF Templar® devoid of catechins
Number of subjects: 64
Study 19605967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HFRT) - 57 Gy in 13 fractions of 3 Gy plus 4 fractions of 4.5 Gy
Number of subjects: 91
Study 19605967 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (CFRT) - 74 Gy in 37 fractions (2 Gy per fraction)
Number of subjects: 91
Study 19605967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HFRT)
Number of subjects: 91
Study 19605967 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (CFRT)
Number of subjects: 91
Study 17890871 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous frusemide infusion
Number of subjects: 59
Study 17890871 — intervention group
Group type: COMPARATOR
Intervention: Regular intermittent intravenous boluses of frusemide
Number of subjects: 59
Study 17890871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 59
Study 15388575 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (Arixtra)
Number of subjects: 54
Study 15388575 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 54
Study 11993614 — intervention group
Group type: EXPERIMENTAL
Intervention: human alphaCGRP (2 microg/min)
Number of subjects: 12
Study 11993614 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 9696954 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release levodopa/carbidopa 200/50 mg after a standard meal (30 min before ingestion)
Number of subjects: 8
Study 9696954 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release levodopa/carbidopa 200/50 mg after fasting (2 hours after ingestion)
Number of subjects: 8
Study 9696954 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release levodopa/carbidopa 200/50 mg after a standard meal
Number of subjects: 8
Study 9696954 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release levodopa/carbidopa 200/50 mg after fasting
Number of subjects: 8
Study 7584018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing (annual screening)
Number of subjects: 0
Study 7584018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing and sigmoidoscopy (early detection)
Number of subjects: 0
Study 7584018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing (case-control study)
Number of subjects: 0
Study 7584018 — intervention group
Group type: COMPARATOR
Intervention: Sigmoidoscopy screening
Number of subjects: 0
Study 2497982 — intervention group
Group type: EXPERIMENTAL
Intervention: Minitran
Number of subjects: 63
Study 2497982 — intervention group
Group type: COMPARATOR
Intervention: Transderm-Nitro (TDN)
Number of subjects: 63
Study 2497982 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 63
Study 29629694 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric lavage with normal saline at 10 mL per kg body weight (n=350)
Number of subjects: 700
Study 29629694 — intervention group
Group type: COMPARATOR
Intervention: No gastric lavage (n=350)
Number of subjects: 700
Study 28681047 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea sweetened with stevia
Number of subjects: 24
Study 28681047 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea sweetened with sucrose
Number of subjects: 24
Study 28681047 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea sweetened with jaggery
Number of subjects: 24
Study 28681047 — intervention group
Group type: COMPARATOR
Intervention: Unsweetened tea (control)
Number of subjects: 24
Study 25512179 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based HIV counseling and testing intervention
Number of subjects: 220
Study 25512179 — intervention group
Group type: COMPARATOR
Intervention: Standard‐of‐care individual HIV testing and counseling intervention
Number of subjects: 220
Study 23448313 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine prescription from clinician A
Number of subjects: 300
Study 23448313 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine prescription from clinician B
Number of subjects: 300
Study 23448313 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine prescription from clinician C
Number of subjects: 300
Study 23448313 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 300
Study 21189109 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemically deposited hydroxyapatite (Bonemaster)
Number of subjects: 50
Study 21189109 — intervention group
Group type: COMPARATOR
Intervention: Plasma-sprayed hydroxyapatite
Number of subjects: 50
Study 19877978 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 40
Study 19877978 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine + Topiramate
Number of subjects: 40
Study 16968585 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059 (8-h and 72-h intravenous infusions)
Number of subjects: 104
Study 16968585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8-h and 72-h intravenous infusions)
Number of subjects: 104
Study 12531493 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down neck extension (HDNE) during lower body negative pressure (LBNP; -40 mmHg)
Number of subjects: 9
Study 12531493 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down neck flexion (HDNF) during lower body negative pressure (LBNP; -40 mmHg)
Number of subjects: 9
Study 12224577 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfadoxine/pyrimethamine plus artesunate
Number of subjects: 30
Study 12224577 — intervention group
Group type: EXPERIMENTAL
Intervention: gametocyte-positive isolates free of subpatent trophozoites
Number of subjects: 30
Study 12224577 — intervention group
Group type: EXPERIMENTAL
Intervention: gametocyte-only isolates
Number of subjects: 30
Study 10806684 — intervention group
Group type: EXPERIMENTAL
Intervention: Third party leukocyte immunization
Number of subjects: 40
Study 10806684 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal leukocyte immunization
Number of subjects: 40
Study 8030596 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil
Number of subjects: 61
Study 8030596 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 61
Study 8030596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Number of subjects: 61
Study 2722729 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole (3 doses of 1 g)
Number of subjects: 69
Study 2722729 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (3 doses of 2 g)
Number of subjects: 69
Study 31532321 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching (ES)
Number of subjects: 0
Study 31532321 — intervention group
Group type: COMPARATOR
Intervention: No scratch (control)
Number of subjects: 0
Study 28606382 — intervention group
Group type: EXPERIMENTAL
Intervention: Caya with ContraGel
Number of subjects: 9
Study 28606382 — intervention group
Group type: EXPERIMENTAL
Intervention: Caya with 3% Nonoxynol-9 (N-9)
Number of subjects: 9
Study 28606382 — intervention group
Group type: EXPERIMENTAL
Intervention: Caya alone
Number of subjects: 9
Study 25363381 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-I
Number of subjects: 22
Study 25363381 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-II
Number of subjects: 22
Study 25363381 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloperoxidase
Number of subjects: 22
Study 25363381 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-IV
Number of subjects: 22
Study 25363381 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B-100
Number of subjects: 22
Study 23517585 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy for at least two months
Number of subjects: 23
Study 23517585 — intervention group
Group type: COMPARATOR
Intervention: Baseline OSA patients
Number of subjects: 23
Study 23517585 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak vascular response following breath hold tests in OSA patients before CPAP therapy
Number of subjects: 23
Study 22364032 — intervention group
Group type: EXPERIMENTAL
Intervention: Buphenine, aminophenazone and diphenylpyraline hydrochloride
Number of subjects: 100
Study 22364032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20205010 — intervention group
Group type: EXPERIMENTAL
Intervention: Values affirmation condition
Number of subjects: 162
Study 20205010 — intervention group
Group type: EXPERIMENTAL
Intervention: Kindness affirmation condition
Number of subjects: 162
Study 20205010 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive traits affirmation condition
Number of subjects: 162
Study 20205010 — intervention group
Group type: COMPARATOR
Intervention: No affirmation control condition
Number of subjects: 162
Study 17114014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting (S)
Number of subjects: 238
Study 17114014 — intervention group
Group type: COMPARATOR
Intervention: No stent (NS)
Number of subjects: 238
Study 15031595 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE)
Number of subjects: 168
Study 15031595 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial infusion chemotherapy (TAI)
Number of subjects: 168
Study 11223117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol (6, 12, or 18 mg/day for 3 weeks)
Number of subjects: 52
Study 11223117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonapride (18 mg/day for 3 weeks)
Number of subjects: 52
Study 9407637 — intervention group
Group type: EXPERIMENTAL
Intervention: Assays for the detection of human parvovirus B19 DNA using PCR techniques; Sensitivity varied among laboratories: 2 laboratories detected the 10(-7) dilution, 1 laboratory failed to detect B19 DNA in any samples, and 5 laboratories obtained false-positive results.
Number of subjects: 17
Study 8425670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponalrestat 600 mg once daily
Number of subjects: 31
Study 8425670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8425670 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 31982096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of Parent Management Training (PMT) and child Cognitive Behavioral Therapy (CBT)
Number of subjects: 120
Study 31982096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of PMT and child CBT
Number of subjects: 120
Study 31982096 — intervention group
Group type: COMPARATOR
Intervention: PMT only
Number of subjects: 120
Study 30735332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50000 IU per week for 8-12 weeks)
Number of subjects: 26
Study 29265084 — intervention group
Group type: EXPERIMENTAL
Intervention: Noophen with standard therapy (n=33)
Number of subjects: 53
Study 29265084 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only (Control group, n=20)
Number of subjects: 53
Study 25451990 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based interactive genetics curriculum
Number of subjects: 121
Study 25451990 — intervention group
Group type: COMPARATOR
Intervention: Control group (genetics review articles)
Number of subjects: 121
Study 23783056 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction on (‐75 mmHg)
Number of subjects: 6
Study 23783056 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction on (‐125 mmHg)
Number of subjects: 6
Study 23783056 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction on (‐400 mmHg)
Number of subjects: 6
Study 23783056 — intervention group
Group type: COMPARATOR
Intervention: Dressing on, no suction
Number of subjects: 6
Study 21306285 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive multifactorial risk factor intervention strategy using single‐pill amlodipine/atorvastatin (5/10, 10/10 mg)
Number of subjects: 1461
Study 21306285 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1461
Study 21306285 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive multifactorial risk factor intervention
Number of subjects: 1461
Study 18769080 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 50 microg/kg with normal saline 1 ml/kg
Number of subjects: 50
Study 18769080 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% 1 ml/kg
Number of subjects: 50
Study 16818967 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/allograft
Number of subjects: 30
Study 16818967 — intervention group
Group type: COMPARATOR
Intervention: autogenous bone graft
Number of subjects: 30
Study 14614669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment, twice daily for 2 weeks
Number of subjects: 0
Study 14614669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14614669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment
Number of subjects: 0
Study 10781652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy with oral 17beta-estradiol or transdermal 17beta-estradiol, and oral norethisterone.
Number of subjects: 26
Study 10781652 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women).
Number of subjects: 26
Study 8835111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 0
Study 8835111 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 0
Study 1482629 — intervention group
Group type: EXPERIMENTAL
Intervention: DermaMend
Number of subjects: 0
Study 1482629 — intervention group
Group type: COMPARATOR
Intervention: A & D
Number of subjects: 0
Study 3975045 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 10
Study 3975045 — intervention group
Group type: COMPARATOR
Intervention: Spectacle correction
Number of subjects: 10
Study 31348235 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-focused rational emotive behavior coaching (REBC)
Number of subjects: 52
Study 31348235 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 30208857 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS) sessions (bipolar, 85 Hz) 2×/week for 12 weeks
Number of subjects: 131
Study 30208857 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group receiving individualized nutritional support
Number of subjects: 131
Study 26449959 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylergonovine and oxytocin infusion
Number of subjects: 0
Study 26449959 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion only
Number of subjects: 0
Study 25467005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention group advised to reduce insoluble dietary fiber and lactose intake
Number of subjects: 130
Study 25467005 — intervention group
Group type: COMPARATOR
Intervention: Standard care group advised to continue their usual diet
Number of subjects: 130
Study 22257710 — intervention group
Group type: COMPARATOR
Intervention: Low transvalvular gradients (≤40 mm Hg)
Number of subjects: 270
Study 22257710 — intervention group
Group type: EXPERIMENTAL
Intervention: High transvalvular gradients (>40 mm Hg)
Number of subjects: 270
Study 23155514 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe recurrent major depression (n=5)
Number of subjects: 45
Study 23155514 — intervention group
Group type: COMPARATOR
Intervention: Control subjects with negligible symptoms of depression (n=4)
Number of subjects: 45
Study 23155514 — intervention group
Group type: COMPARATOR
Intervention: Random non-clinical sample of women (n=40)
Number of subjects: 45
Study 17337179 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held Neurotip tester pin
Number of subjects: 0
Study 17337179 — intervention group
Group type: COMPARATOR
Intervention: Neuropen (spring loaded system)
Number of subjects: 0
Study 16358163 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Sedation (PCS) with midazolam: loading dose 0.028 mg/kg, bolus dose 1 mg, lock-out period 5 min, basal infusion rate 0.
Number of subjects: 40
Study 16358163 — intervention group
Group type: COMPARATOR
Intervention: Control group received 1 microg/kg of fentanyl (i.v.) and 0.028 mg/kg of midazolam (i.v.).
Number of subjects: 40
Study 11942259 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized firm system approach with point-of-service reminders and pharmacist outreach program
Number of subjects: 0
Study 11942259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 11942259 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized firm system approach
Number of subjects: 0
Study 9585654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 5 mg
Number of subjects: 30
Study 9585654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 10 mg
Number of subjects: 30
Study 9585654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 15 mg
Number of subjects: 30
Study 9585654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 20 mg
Number of subjects: 30
Study 9585654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9585654 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (positive control)
Number of subjects: 30
Study 7815676 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCTs) infusion (0.07 g/kg.h‐1)
Number of subjects: 19
Study 7815676 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCTs) and long-chain triglycerides (LCTs) mixture infusion (50/50%, 0.07 g/kg.h‐1)
Number of subjects: 19
Study 7815676 — intervention group
Group type: COMPARATOR
Intervention: Control group (glucose infusion only)
Number of subjects: 19
Study 2651632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (30‐40 mg/kg/day)
Number of subjects: 32
Study 2651632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 786504 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible disfigurement (photograph of a girl with post‐operative disfigurement)
Number of subjects: 60